Appendix cancer is rare. That single fact shapes almost everything about the road a patient travels, from how long a diagnosis takes to who ends up holding the scalpel. It is also the reason appendix cancer expert centers matter so much. A new perspective piece in Annals of Surgical Oncology lays out the argument plainly, and while it is written for surgeons in Europe, the lesson lands squarely on this community.

The authors, who help run France’s national network for rare peritoneal cancers, make a claim that sounds obvious once you hear it. In a rare cancer, the biggest problem is often not the biology. It is the way care is organized. Common cancers have standardized playbooks, thousands of patients in trials, and local doctors who see the disease every week. Rare cancers have none of that. So patients get delay, misdiagnosis, and wildly uneven access to the few people who truly understand the disease.

The problem is not only the tumor. It is the map.

Most people in this group know the diagnostic odyssey by heart. Months of being told it was nothing. An appendectomy for what looked like appendicitis, then a pathology report that changed everything. A first read that turned out to be wrong when a specialist looked again. The paper puts a name to this pattern. Rare cancers carry a high rate of initial diagnostic disagreement, which means the label a patient starts with is not always the label they deserve. When the map is wrong, every turn after it is wrong too.

Expertise should travel to you

The fix the authors describe is not a new drug. It is a structure. They call it hub and spoke. A small number of expert centers act as hubs, deeply connected to local hospitals that act as spokes. The idea is simple. Send the expertise to the patient rather than making the patient chase it across the country. Patients keep their care close to home when they can, and get expert eyes on the decisions that matter most.

Not every network that calls itself expert actually functions like one. The paper points to three features that separate the real thing from a name on a website.

First, referral to an expert center happens before treatment is locked in, not after a first surgery has already set the course. Second, pathology gets reviewed by people who read appendiceal cases all the time. Third, the treatment plan comes out of a room where a surgical oncologist, a medical oncologist, a pathologist, a radiologist, and increasingly a patient representative all weigh in together. One person guessing in isolation is exactly the failure mode this structure is built to prevent.

The physicians who advise Appendicure practice at exactly these kinds of centers. That is not an accident. It is the whole point.

Why the pathology read is the whole ballgame

In appendix cancer, the pathology report drives everything. A low-grade mucinous neoplasm, a mucinous adenocarcinoma, a goblet cell adenocarcinoma, and a signet ring cell tumor are different diseases with different paths, even though they all started in the same small organ. The 2025 Godfrey consensus guidelines for appendiceal cancer treat grade and subtype as the foundation of every treatment decision. Get the read right and the plan can be right. Get it wrong and everything downstream inherits the mistake. This is the single strongest argument for having a specialist look before anyone commits to a plan.

In a rare cancer, no case can be wasted

Here the paper says something that should be printed on a wall. When a disease is rare, every single case is scientifically valuable, so letting that data sit locked in one hospital’s files is not just inefficient. It is unethical. The answer is a registry. Pool cases across cities and countries, and patterns start to appear that no single center could ever see, because no single center has enough patients to see them.

That is the entire reason the Patient-Led Global Appendix Cancer Registry exists. It is IRB approved with an exempt determination, and it is live. The registry is HIPAA compliant and GDPR compliant. Every person who enters their story adds a data point that a researcher can actually use. There are two ways to join, one for participants in the United States and one for everyone else.

Join the registry (United States)
Join the registry (outside the United States)

In France, a national network organized this way reported that after it started building the structure in 2011, the time from diagnosis to first treatment dropped to roughly a third of what it had been. That figure comes from rare peritoneal cancer patients in Europe, not from appendix cancer specifically, so it is a picture of what structure makes possible, not a promise. The mechanism is the point. Organized care and shared data move faster than scattered care and siloed files.

Patients as partners, not subjects

The part of this paper that matters most to a patient-led nonprofit is the shift in who holds the pen. For a long time, patients were the people research happened to. The authors describe a different model, one where patients sit on steering committees, help set research priorities, and insist that studies measure the things patients actually live with, like quality of life, the ability to keep working, and the financial toll of treatment, not survival alone.

This is not a fringe idea anymore. It is where the money is going. The paper names United States funders like the Congressionally Directed Medical Research Programs Rare Cancers Research Program and the Patient-Centered Outcomes Research Institute, both of which reward research that builds patients in from the start. A patient-led registry is not a nice-to-have in that world. It is the asset that makes the research possible.

What you can do with this

Three things, and none of them require a medical degree. Ask whether your pathology has been reviewed by a center that reads appendiceal cases regularly, and request that review if it has not. Ask your care team about referral to a high-volume center for the big decisions, especially anything involving cytoreductive surgery. And add your case to the registry, whether you are in the United States or another country, because the next patient’s answers may be hiding in your data.

If you have surgery coming up, save your tissue for research

There is one more thing worth setting up before an operation, and it costs nothing. When a tumor is removed, there is often more tissue than the lab needs for your care. The extra is usually thrown away or frozen and forgotten. It does not have to be. A nonprofit called Pattern.org, run by the Rare Cancer Research Foundation, routes that leftover tissue to scientists who study rare cancers. For appendix cancer and pseudomyxoma peritonei, the samples go to the Broad Institute of MIT and Harvard, where researchers use them to build living models of the disease. Those are the same kinds of models behind much of the research covered on this site.

The part that matters for a patient is how little it asks of you. Register and give consent online before your surgery. Pattern.org handles the rest with your surgical team and your hospital. There is no cost, and it does not change your own treatment in any way, because only tissue you did not need is collected. Your information is stripped of anything identifying before it ever reaches a lab. One limit to know. Right now Pattern.org can only collect tissue from procedures inside the continental United States. If your surgery is elsewhere, the program cannot take your sample yet. If it is in the United States, the time to set it up is before the operation, not after.

The evidence that this model works already exists. What is missing is not knowledge. It is putting it into practice, one patient and one shared story at a time. If you want to help build that, you can support Appendicure here.

Read more

Preserving Tumor Tissue Before Appendix Cancer Surgery
Not All Appendix Cancers Are the Same, and That Distinction Changes Everything
CRS-HIPEC Surgeon Volume: Why the Whole Team Matters

Source: Villeneuve L, Kepenekian V, Glehen O. Networking is Essential for the Proper Management of Rare Cancers: From Recognition to Implementation. Annals of Surgical Oncology, 2026.